Copyright © 2012 Javier Blesa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. A. J. Lees, J. Hardy, and T. Revesz, “Parkinson's disease,” The Lancet, vol. 373, no. 9680, pp. 2055–2066, 2009. View at Publisher · View at Google Scholar · View at Scopus
2. M. G. Spillantini, M. L. Schmidt, V. M. Y. Lee, J. Q. Trojanowski, R. Jakes, and M. Goedert, “α-synuclein in Lewy bodies [8],” Nature, vol. 388, no. 6645, pp. 839–840, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
3. L. S. Forno, “Neuropathology of Parkinson's disease,” Journal of Neuropathology and Experimental Neurology, vol. 55, no. 3, pp. 259–272, 1996. View at Scopus
4. H. Braak, E. Ghebremedhin, U. Rüb, H. Bratzke, and K. Del Tredici, “Stages in the development of Parkinson's disease-related pathology,” Cell and Tissue Research, vol. 318, no. 1, pp. 121–134, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
5. K. R. Chaudhuri, D. G. Healy, and A. H. V. Schapira, “Non-motor symptoms of Parkinson's disease: diagnosis and management,” Lancet Neurology, vol. 5, no. 3, pp. 235–245, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
6. W. Dauer and S. Przedborski, “Parkinson's disease: mechanisms and models,” Neuron, vol. 39, no. 6, pp. 889–909, 2003. View at Publisher · View at Google Scholar · View at Scopus
7. A. Carlsson, M. Lindqvist, and T. Magnusson, “3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists,” Nature, vol. 180, no. 4596, p. 1200, 1957. View at Publisher · View at Google Scholar · View at Scopus
8. A. Carlsson, “The occurrence, distribution and physiological role of catecholamines in the nervous system,” Pharmacological reviews, vol. 11, no. 2, pp. 490–493, 1959. View at Scopus
9. R. Betarbet, T. B. Sherer, and J. Timothy Greenamyre, “Animal models of Parkinson's disease,” BioEssays, vol. 24, no. 4, pp. 308–318, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
10. T. M. Dawson, H. S. Ko, and V. L. Dawson, “Genetic Animal Models of Parkinson's Disease,” Neuron, vol. 66, no. 5, pp. 646–661, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
11. R. K. W. Schwarting and J. P. Huston, “Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae,” Progress in Neurobiology, vol. 49, no. 3, pp. 215–266, 1996. View at Publisher · View at Google Scholar · View at Scopus
12. R. K. W. Schwarting and J. P. Huston, “The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments,” Progress in Neurobiology, vol. 50, no. 2-3, pp. 275–331, 1996. View at Publisher · View at Google Scholar · View at Scopus
13. R. K. W. Schwarting and J. P. Huston, “Behavioral and neurochemical dynamics of neurotoxic meso-striatal dopamine lesions,” NeuroToxicology, vol. 18, no. 3, pp. 689–708, 1997. View at Scopus
14. S. Senoh and B. Witkop, “Non-enzymatic conversions of dopamine to norepinephrine and trihydroxyphenethylamines,” Journal of the American Chemical Society, vol. 81, no. 23, pp. 6222–6231, 1959. View at Scopus
15. U. Ungerstedt, “6-hydroxy-dopamine induced degeneration of central monoamine neurons,” European Journal of Pharmacology, vol. 5, no. 1, pp. 107–110, 1968. View at Scopus
16. T. A. P. Roeling, G. J. Docter, P. Voorn, B. P. C. Melchers, E. C. Wolters, and H. J. Groenewegen, “Effects of unilateral 6-hydroxydopamine lesions on neuropeptide immunoreactivity in the basal ganglia of the common marmoset, Callithrix jacchus, a quantitative immunohistochemical analysis,” Journal of Chemical Neuroanatomy, vol. 9, no. 3, pp. 155–164, 1995. View at Publisher · View at Google Scholar · View at Scopus
17. H. Valette, P. Deleuze, A. Syrota et al., “Canine myocardial beta-adrenergic, muscarinic receptor densities after denervation: a PET study,” Journal of Nuclear Medicine, vol. 36, no. 1, pp. 140–146, 1995. View at Scopus
18. L. E. Annett, E. M. Torres, D. J. Clarke et al., “Survival of nigral grafts within the striatum of marmosets with 6-OHDA lesions depends critically on donor embryo age,” Cell Transplantation, vol. 6, no. 6, pp. 557–569, 1997. View at Publisher · View at Google Scholar · View at Scopus
19. R. Ruffy and M. Leonard, “Chemical cardiac sympathetic denervation hampers defibrillation in the dog,” Journal of Cardiovascular Electrophysiology, vol. 8, no. 1, pp. 62–67, 1997. View at Scopus
20. C. Sachs and G. Jonsson, “Mechanisms of action of 6-hydroxydopamine,” Biochemical Pharmacology, vol. 24, no. 1, pp. 1–8, 1975. View at Scopus
21. G. E. Martin, R. D. Myers, and D. C. Newberg, “Catecholamine release by intracerebral perfusion of 6 hydroxydopamine and desipramine,” European Journal of Pharmacology, vol. 36, no. 2, pp. 299–311, 1976. View at Scopus
22. D. A. Perese, J. Ulman, J. Viola, S. E. Ewing, and K. S. Bankiewicz, “A 6-hydroxydopamine-induced selective parkinsonian rat model,” Brain Research, vol. 494, no. 2, pp. 285–293, 1989. View at Scopus
23. S. Przedborski, M. Levivier, H. Jiang et al., “Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine,” Neuroscience, vol. 67, no. 3, pp. 631–647, 1995. View at Publisher · View at Google Scholar · View at Scopus
24. G. Cohen, “Oxy-radical toxicity in catecholamine neurons,” NeuroToxicology, vol. 5, no. 1, pp. 77–82, 1984. View at Scopus
25. F. Blandini, M. T. Armentero, and E. Martignoni, “The 6-hydroxydopamine model: news from the past,” Parkinsonism and Related Disorders, vol. 14, no. 2, pp. S124–S129, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
26. H. Sauer and W. H. Oertel, “Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat,” Neuroscience, vol. 59, no. 2, pp. 401–415, 1994. View at Publisher · View at Google Scholar · View at Scopus
27. C. S. Lee, H. Sauer, and A. Björklund, “Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat,” Neuroscience, vol. 72, no. 3, pp. 641–653, 1996. View at Publisher · View at Google Scholar · View at Scopus
28. U. Ungerstedt, “Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system,” Acta Physiologica Scandinavica, Supplement, vol. 367, pp. 95–122, 1971.
29. W. M. Bourn, L. Chin, and A. L. Picchioni, “Enhancement of audiogenic seizure by 6-hydroxydopamine,” Journal of Pharmacy and Pharmacology, vol. 24, no. 11, pp. 913–914, 1972. View at Scopus
30. J. Knoll, “The pharmacology of (-)deprenyl,” Journal of Neural Transmission. Supplementum, vol. 22, pp. 75–89, 1986. View at Scopus
31. J. D. Graham, M. J. Lewis, and J. Williams, “Proceedings: The effect of delta-1-tetrahydrocannabinol on the noradrenaline and dopamine content of the brain and heart of the rat,” British Journal of Pharmacology, vol. 52, no. 3, p. 446, 1974. View at Scopus
32. J. W. Langston, P. Ballard, J. W. Tetrud, and I. Irwin, “Chronic parkinsonism in humans due to a product of meperidine-analog synthesis,” Science, vol. 219, no. 4587, pp. 979–980, 1983. View at Scopus
33. L. S. Forno, L. E. DeLanney, I. Irwin, and J. W. Langston, “Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations,” Advances in neurology, vol. 60, pp. 600–608, 1993. View at Scopus
34. G. Halliday, M. T. Herrero, K. Murphy et al., “No Lewy pathology in monkeys with over 10 years of severe MPTP parkinsonism,” Movement Disorders, vol. 24, no. 10, pp. 1519–1523, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
35. N. W. Kowall, P. Hantraye, E. Brouillet, M. F. Beal, A. C. McKee, and R. J. Ferrante, “MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons,” NeuroReport, vol. 11, no. 1, pp. 211–213, 2000. View at Scopus
36. F. Fornai, O. M. Schlüter, P. Lenzi et al., “Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and α-synuclein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 9, pp. 3413–3418, 2005. View at Publisher · View at Google Scholar · View at PubMed
37. M. Cui, R. Aras, W. V. Christian et al., “The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 19, pp. 8043–8048, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
38. J. A. Javitch, R. J. D'Amato, S. M. Strittmatter, and S. H. Snyder, “Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 82, no. 7, pp. 2173–2177, 1985. View at Scopus
39. E. Bezard, C. E. Gross, M. C. Fournier, S. Dovero, B. Bloch, and M. Jaber, “Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter,” Experimental Neurology, vol. 155, no. 2, pp. 268–273, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
40. R. R. Gainetdinov, F. Fumagalli, Y. M. Wang et al., “Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice,” Journal of Neurochemistry, vol. 70, no. 5, pp. 1973–1978, 1998. View at Scopus
41. T. S. Guillot, K. R. Shepherd, J. R. Richardson et al., “Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis,” Journal of Neurochemistry, vol. 106, no. 5, pp. 2205–2217, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
42. T. S. Guillot and G. W. Miller, “Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons,” Molecular Neurobiology, vol. 39, no. 2, pp. 149–170, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
43. W. J. Burke, V. B. Kumar, N. Pandey et al., “Aggregation of α-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine,” Acta Neuropathologica, vol. 115, no. 2, pp. 193–203, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
44. W. M. Panneton, V. B. Kumar, Q. Gan, W. J. Burke, and J. E. Galvin, “The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis,” PLoS One, vol. 5, no. 12, Article ID e15251, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
45. M. J. Zigmond, T. W. Berger, A. A. Grace, and E. M. Stricker, “Compensatory responses to nigrostriatal bundle injury. Studies with 6-hydroxydopamine in an animal model of parkinsonism,” Molecular and Chemical Neuropathology, vol. 10, no. 3, pp. 185–200, 1989. View at Scopus
46. C. C. Chiueh, S. P. Markey, and R. S. Burns, “Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat,” European Journal of Pharmacology, vol. 100, no. 2, pp. 189–194, 1984.
47. S. Przedborski, V. Jackson-Lewis, A. B. Naini et al., “The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety,” Journal of Neurochemistry, vol. 76, no. 5, pp. 1265–1274, 2001. View at Publisher · View at Google Scholar · View at Scopus
48. J. W. Langston, E. B. Langston, and I. Irwin, “MPTP-induced parkinsonism in human and non-human primates—clinical and experimental aspects,” Acta Neurologica Scandinavica, vol. 70, supplement 100, pp. 49–54, 1984.
49. K. S. Bankiewicz, E. H. Oldfield, and C. C. Chiueh, “Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),” Life Sciences, vol. 39, no. 1, pp. 7–16, 1986.
50. M. M. Iravani, E. Syed, M. J. Jackson, L. C. Johnston, L. A. Smith, and P. Jenner, “A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets,” European Journal of Neuroscience, vol. 21, no. 4, pp. 841–854, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
51. P. Hantraye, M. Varastet, M. Peschanski et al., “Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons,” Neuroscience, vol. 53, no. 1, pp. 169–178, 1993. View at Publisher · View at Google Scholar · View at Scopus
52. E. Bezard, C. Imbert, X. Deloire, B. Bioulac, and C. E. Gross, “A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey,” Brain Research, vol. 766, no. 1-2, pp. 107–112, 1997. View at Publisher · View at Google Scholar · View at Scopus
53. S. Mounayar, S. Boulet, D. Tandé et al., “A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery,” Brain, vol. 130, no. 11, pp. 2898–2914, 2007. View at Publisher · View at Google Scholar · View at PubMed
54. J. Blesa, C. Juri, M. Collantes et al., “Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An 18F-DOPA and 11C-DTBZ PET study,” Neurobiology of Disease, vol. 38, no. 3, pp. 456–463, 2010. View at Publisher · View at Google Scholar · View at PubMed
55. A. Ovadia, Z. Zhang, and D. M. Gash, “Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys,” Neurobiology of Aging, vol. 16, no. 6, pp. 931–937, 1995. View at Publisher · View at Google Scholar · View at Scopus
56. M. Pessiglione, D. Guehl, E. C. Hirsch, J. Féger, and L. Tremblay, “Disruption of self-organized actions in monkeys with progressive MPTP-induced parkinsonism. I. Effects of task complexity,” European Journal of Neuroscience, vol. 19, no. 2, pp. 426–436, 2004. View at Publisher · View at Google Scholar · View at Scopus
57. JS Schneider, Modeling Cognitive Deficits Associated with Parkinsonism in the Chronic-Low-Dose MPTP-Treated Monkey, CRC Press, Boca Raton, Fla, USA, 2006.
58. G. Anderson, A. R. Noorian, G. Taylor et al., “Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease,” Experimental Neurology, vol. 207, no. 1, pp. 4–12, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
59. S. H. Fox, R. Chuang, and J. M. Brotchie, “Serotonin and Parkinson's disease: on movement, mood, and madness,” Movement Disorders, vol. 24, no. 9, pp. 1255–1266, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
60. Q. Barraud, I. Obeid, I. Aubert et al., “Neuroanatomical study of the A11 diencephalospinal pathway in the non-human primate,” PLoS One, vol. 5, no. 10, Article ID e13306, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
61. J. Vezoli, K. Fifel, V. Leviel et al., “Early presymptomatic and long-term changes of rest activity cycles and cognitive behavior in a MPTP-monkey model of Parkinson's disease,” PLoS One, vol. 6, no. 8, Article ID e23952, 2011. View at Publisher · View at Google Scholar · View at PubMed
62. H. Bergman, T. Wichmann, and M. R. DeLong, “Reversal of experimental Parkinsonism by lesions of the subthalamic nucleus,” Science, vol. 249, no. 4975, pp. 1436–1438, 1990. View at Scopus
63. J. Guridi, M. T. Herrero, M. R. Luquin et al., “Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis,” Brain, vol. 119, no. 5, pp. 1717–1727, 1996. View at Publisher · View at Google Scholar · View at Scopus
64. E. Bezard and S. Przedborski, “A tale on animal models of Parkinson's Disease,” Movement Disorders, vol. 26, no. 6, pp. 993–1002, 2011. View at Publisher · View at Google Scholar · View at PubMed
65. M. Vila, V. Jackson-Lewis, S. Vukosavic et al., “Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 5, pp. 2837–2842, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
66. W. Dauer, N. Kholodilov, M. Vila et al., “Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 22, pp. 14524–14529, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
67. C. Berry, C. La Vecchia, and P. Nicotera, “Paraquat and parkinson's disease,” Cell Death and Differentiation, vol. 17, no. 7, pp. 1115–1125, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
68. B. J. Day, M. Patel, L. Calavetta, L. Y. Chang, and J. S. Stamler, “A mechanism of paraquat toxicity involving nitric oxide synthase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 22, pp. 12760–12765, 1999. View at Publisher · View at Google Scholar · View at Scopus
69. S. Przedborski and H. Ischiropoulos, “Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease,” Antioxidants and Redox Signaling, vol. 7, no. 5-6, pp. 685–693, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
70. A. I. Brooks, C. A. Chadwick, H. A. Gelbard, D. A. Cory-Slechta, and H. J. Federoff, “Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss,” Brain Research, vol. 823, no. 1-2, pp. 1–10, 1999. View at Publisher · View at Google Scholar · View at Scopus
71. A. L. McCormack, M. Thiruchelvam, A. B. Manning-Bog et al., “Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat,” Neurobiology of Disease, vol. 10, no. 2, pp. 119–127, 2002. View at Publisher · View at Google Scholar · View at Scopus
72. C. Thiffault, J. W. Langston, and D. A. Di Monte, “Increased striatal dopamine turnover following acute administration of rotenone to mice,” Brain Research, vol. 885, no. 2, pp. 283–288, 2000. View at Publisher · View at Google Scholar · View at Scopus
73. M. Thiruchelvam, B. J. Brockel, E. K. Richfield, R. B. Baggs, and D. A. Cory-Slechta, “Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease?” Brain Research, vol. 873, no. 2, pp. 225–234, 2000. View at Publisher · View at Google Scholar · View at Scopus
74. P. M. Rappold, M. Cui, A. S. Chesser et al., “Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 51, pp. 20766–20771, 2011. View at Publisher · View at Google Scholar · View at PubMed
75. A. B. Manning-Bog, A. L. McCormack, J. Li, V. N. Uversky, A. L. Fink, and D. A. Di Monte, “The herbicide paraquat causes up-regulation and aggregation of α-synuclein in mice: paraquat and α-synuclein,” Journal of Biological Chemistry, vol. 277, no. 3, pp. 1641–1644, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
76. R. N. Takahashi, R. Rogerio, and M. Zanin, “Maneb enhances MPTP neurotoxicity in mice,” Research Communications in Chemical Pathology and Pharmacology, vol. 66, no. 1, pp. 167–170, 1989.
77. A. Kachroo, M. C. Irizarry, and M. A. Schwarzschild, “Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration,” Experimental Neurology, vol. 223, no. 2, pp. 657–661, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
78. P. G. Butterfield, B. G. Valanis, P. S. Spencer, C. A. Lindeman, and J. G. Nutt, “Environmental antecedents of young-onset Parkinson's disease,” Neurology, vol. 43, no. 6, pp. 1150–1158, 1993. View at Scopus
79. J. M. Gorell, C. C. Johnson, B. A. Rybicki, E. L. Peterson, and R. J. Richardson, “The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living,” Neurology, vol. 50, no. 5, pp. 1346–1350, 1998. View at Scopus
80. B. K. Barlow, E. K. Richfield, D. A. Cory-Slechta, and M. Thiruchelvam, “A fetal risk factor for Parkinson's disease,” Developmental Neuroscience, vol. 26, no. 1, pp. 11–23, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
81. C. C. Tang, K. L. Poston, V. Dhawan, and D. Eidelberg, “Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease,” Journal of Neuroscience, vol. 30, no. 3, pp. 1049–1056, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
82. C. M. Tanner, F. Kame, G. W. Ross et al., “Rotenone, paraquat, and Parkinson's disease,” Environmental Health Perspectives, vol. 119, no. 6, pp. 866–872, 2011. View at Publisher · View at Google Scholar · View at PubMed
83. J. Hisata, Lake and stream rehabilitation: rotenone use and health risks. Final supplemental environmental impact statement, Washington Satet Deparment of Fish and Wildlife, 2002.
84. M. Inden, Y. Kitamura, H. Takeuchi et al., “Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone,” Journal of Neurochemistry, vol. 101, no. 6, pp. 1491–1504, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
85. M. Inden, Y. Kitamura, M. Abe, A. Tamaki, K. Takata, and T. Taniguchi, “Parkinsonian rotenone mouse model: reevaluation of long-term administration of rotenone in C57BL/6 mice,” Biological and Pharmaceutical Bulletin, vol. 34, no. 1, pp. 92–96, 2011. View at Publisher · View at Google Scholar
86. R. Betarbet, T. B. Sherer, G. MacKenzie, M. Garcia-Osuna, A. V. Panov, and J. T. Greenamyre, “Chronic systemic pesticide exposure reproduces features of Parkinson's disease,” Nature Neuroscience, vol. 3, no. 12, pp. 1301–1306, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
87. M. Alam, A. Mayerhofer, and W. J. Schmidt, “The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA,” Behavioural Brain Research, vol. 151, no. 1-2, pp. 117–124, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
88. J. R. Cannon, V. Tapias, H. M. Na, A. S. Honick, R. E. Drolet, and J. T. Greenamyre, “A highly reproducible rotenone model of Parkinson's disease,” Neurobiology of Disease, vol. 34, no. 2, pp. 279–290, 2009. View at Publisher · View at Google Scholar · View at Scopus
89. G. U. Höglinger, J. Féger, A. Prigent et al., “Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats,” Journal of Neurochemistry, vol. 84, no. 3, pp. 491–502, 2003. View at Publisher · View at Google Scholar
90. T. B. Sherer, J. H. Kim, R. Betarbet, and J. T. Greenamyre, “Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and α-synuclein aggregation,” Experimental Neurology, vol. 179, no. 1, pp. 9–16, 2003. View at Publisher · View at Google Scholar · View at Scopus
91. Y.-N. Wu and S. W. Johnson, “Dopamine oxidation facilitates rotenone-dependent potentiation of N-methyl-d-aspartate currents in rat substantia nigra dopamine neurons,” Neuroscience, vol. 195, pp. 138–144, 2011. View at Publisher · View at Google Scholar · View at PubMed
92. R. J. Ferrante, J. B. Schulz, N. W. Kowall, and M. F. Beal, “Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra,” Brain Research, vol. 753, no. 1, pp. 157–162, 1997. View at Publisher · View at Google Scholar · View at Scopus
93. H. Takeuchi, T. Yanagida, M. Inden et al., “Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models,” Journal of Neuroscience Research, vol. 87, no. 2, pp. 576–585, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
94. F. Pan-Montojo, O. Anichtchik, Y. Dening et al., “Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice,” PLoS One, vol. 5, no. 1, Article ID e8762, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
95. F. J. Pan-Montojo and R. H. W. Funk, “Oral administration of rotenone using a gavage and image analysis of alpha-synuclein inclusions in the enteric nervous system,” Journal of Visualized Experiments, no. 44, Article ID e2123, 2010. View at Publisher · View at Google Scholar · View at PubMed
96. R. Krüger, W. Kuhn, T. Müller et al., “Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease,” Nature Genetics, vol. 18, no. 2, pp. 106–108, 1998.
97. B. I. Giasson, J. E. Duda, S. M. Quinn, B. Zhang, J. Q. Trojanowski, and V. M. Y. Lee, “Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein,” Neuron, vol. 34, no. 4, pp. 521–533, 2002. View at Publisher · View at Google Scholar · View at Scopus
98. E. Masliah, E. Rockenstein, I. Veinbergs et al., “Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders,” Science, vol. 287, no. 5456, pp. 1265–1269, 2000. View at Publisher · View at Google Scholar · View at Scopus
99. A. Abeliovich, Y. Schmitz, I. Fariñas et al., “Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system,” Neuron, vol. 25, no. 1, pp. 239–252, 2000. View at Scopus
100. B. Thomas, A. S. Mandir, N. West et al., “Resistance to MPTP-Neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activation,” PLoS One, vol. 6, no. 1, Article ID e16706, 2011. View at Publisher · View at Google Scholar · View at PubMed
101. M. B. Feany and W. W. Bender, “A Drosophila model of Parkinson's disease,” Nature, vol. 404, no. 6776, pp. 394–398, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
102. D. Wang, B. Tang, G. Zhao et al., “Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons,” Molecular Neurodegeneration, vol. 3, no. 1, article no. 3, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
103. A. Zimprich, S. Biskup, P. Leitner et al., “Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology,” Neuron, vol. 44, no. 4, pp. 601–607, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
104. Y. Li, W. Liu, T. F. Oo et al., “Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease,” Nature Neuroscience, vol. 12, no. 7, pp. 826–828, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
105. D. J. Moore and T. M. Dawson, “Value of genetic models in understanding the cause and mechanisms of Parkinson's disease,” Current Neurology and Neuroscience Reports, vol. 8, no. 4, pp. 288–296, 2008. View at Publisher · View at Google Scholar · View at Scopus
106. J.-H. Shin, H. S. Ko, H. Kang et al., “PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in parkinson's disease,” Cell, vol. 144, no. 5, pp. 689–702, 2011. View at Publisher · View at Google Scholar · View at PubMed
107. J. Peng, M. L. Oo, and J. K. Andersen, “Synergistic effects of environmental risk factors and gene mutations in Parkinson's disease accelerate age-related neurodegeneration,” Journal of Neurochemistry, vol. 115, no. 6, pp. 1363–1373, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus